The influence of estrogen on migraine: A systematic review

JAMA

Volumn 295, Issue 15, 2006, Pages 1824-1830

  Brandes, Jan Lewis ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Nashville Neuroscience Group   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN; CORTICOSTEROID; ERGOT ALKALOID; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FROVATRIPTAN; HORMONE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PROGESTERONE; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBASE; EPIDEMIOLOGICAL DATA; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HORMONE SENSITIVITY; HUMAN; MEDLINE; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; META ANALYSIS; MIGRAINE; MIGRAINE WITHOUT AURA; NONHUMAN; ORAL CONTRACEPTION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; PURE MENSTRUAL MIGRAINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; FEMALE; MENOPAUSE; MENSTRUATION; PHYSIOLOGY; PREGNANCY;

ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MENSTRUATION; MIGRAINE DISORDERS; PREGNANCY;

EID: 33645824769     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.15.1824     Document Type: Review

References (76)

1. Welch KM, Darnley D, Simkins RT. The role of estrogen in migraine: a review and hypothesis. Cephalalgia. 1984;4:227-236.
2. Somerville BW. The role of progesterone in menstrual migraine. Neurology. 1971;21:853-859.
3. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22:355-365.
4. Somerville BW. Estrogen-withdrawal migraine, I: duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology. 1975;25:239-244.
5. Somerville BW. Estrogen-withdrawal migraine, II: attempted prophylaxis by continuous estradiol administration. Neurology. 1975;25:245-250.
6. MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15(suppl 3):143-153.
7. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
8. Couturier EGM, Bomhof MAM, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
9. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55:1517-1523.
10. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia. 1990;10:305-310.
11. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707-716.
12. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
13. Facchinetti F, Neri I, Martignoni E, Fioroni L, Nappi G, Genazzani AR. The association of menstrual migraine with the premenstrual syndrome. Cephalalgia. 1993;13:422-425.
14. Martin VT, Wernke S, Mandell K, et al. Symptoms of premenstrual syndrome and their association with migraine headache. Headache. 2006;46:125-137.
15. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia. 1997;17:488-491.
16. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
17. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
18. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in1300 women. Headache. 1993;33:385-389.
19. Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology. 1995;45:1076-1082.
20. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
21. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep. 2004;8:229-237.
22. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20:701-707.
23. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache. 2003;43:27-35.
24. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23:197-205.
25. Scharff L, Marcus DA, Turk DC. Headache during pregnancy and in the postpartum: a prospective study. Headache. 1997;37:203-210.
26. Somerville BW. A study of migraine in pregnancy. Neurology. 1972;22:824-828.
27. Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache. 1999;39:625-632.
28. Wall VR. Breastfeeding and migraine headaches. J Hum Lact. 1992;8:209-212.
29. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993;17:31-37.
30. Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003;12:1027-1036.
31. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. Evidence of a genetic factor in migraine with aura: apopulation-based Danish twin study. Ann Neurol. 1999;45: 242-246.
32. Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB. The relative role of genetic and environmental factors in migraine without aura. Neurology. 1999;53:995-999.
33. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res. 2003;111:84-90.
34. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000;96:762-764.
35. Oterino A, Valle N, Bravo Y, et al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia. 2004;24:491-494.
36. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics. 2004;5:129-133.
37. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
38. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR. Investigation of hormone receptor genes in migraine. Neurogenetics. 2005;6:17-23.
39. Amir B-Y, Yaacov B, Guy B, Gad P, Itzhak W, Gal I. Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache. 2005;45:215-219.
40. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache. 1996;36:367-371.
41. Facchinetti F, Nappi RE, Tirelli A, Polatti F, Nappi G. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002;42:924-929.
42. Kudrow L. Migraine in women: recognizing hormonal influences. Female Patient Total Health Care Women. 1993;18:33-38.
43. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis-part I. Headache. 2006;46:3-23.
44. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:401-406.
45. Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 2003;83:965-1016.
46. Sarchielli P, Tognoloni M, Russo S, et al. Variations in the platelet arginine/nitric oxide pathway during the ovarian cycle in females affected by menstrual migraine. Cephalalgia. 1996;16:468-475.
47. Fioroni L, Martignoni E, Facchinetti F. Changes of neuroendocrine axes in patients with menstrual migraine. Cephalalgia. 1995;15:297-300.
48. Benedetto C, Allais G, Ciochetto D, De Lorenzo C. Pathophysiological aspects of menstrual migraine. Cephalalgia. 1997;17(suppl 20):32-34.
49. Puri V, Puri S, Svojanovsky S, et al. Effects of oestrogen on trigeminal ganglia in culture: implications for hormonal effects on migraine. Cephalalgia. 2006;26:33-42.
50. Splett CL, Scheffen JR, Desotelle JA, Plamann V, Bauer-Dantoin AC. Galanin enhancement of gonadotropin-releasing hormone-stimulated luteinizing hormone secretion in female rats is estrogen dependent. Endocrinology. 2003;144:484-490.
51. Puri V, Cui L, Liverman CS, et al. Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides. 2005;39:409-417.
52. Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology. 2004;29:2035-2045.
53. Nappi RE, Sances G, Brundu B, et al. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod. 2005;20:3423-3428.
54. Facchinetti F, Sgarbi L, Piccinini F. Hypothalamic resetting at puberty and the sexual dimorphism of migraine. Funct Neurol. 2000;15(suppl 3):137-142.
55. Facchinetti F, Martignoni E, Fioroni L, Sances G, Genazzani AR. Opioid control of the hypothalamus pituitary-adrenal axis cyclically fails in menstrual migraine. Cephalalgia. 1990;10:51-56.
56. de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. BMJ. 1986;293: 1540.
57. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2:113-120.
58. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004;97:819-822.
59. Smits MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34:103-106.
60. Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170-174.
61. Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine: the Sumatriptan Menstrual Migraine study group. Obstet Gynecol. 1995;86:911-916.
62. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44:120-130.
63. Landy S, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58:913-919.
64. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol. 1993;82:769-772.
65. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96: 237-242.
66. Geraud G, Lanteri-Minet M, Lucas C, Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004;26:1305-1318.
67. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management for acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849.
68. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Available at: http://www.neurology.org/cgi/reprint/55/6/754.pdf. Accessed March 23, 2006.
69. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41:248-256.
70. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
71. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
72. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705-709.
73. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307-309.
74. Moschiano F, Allais G, Grazzi L, et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci. 2005;26(suppl 2):S162-S166.
75. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW. Mental disorders and the incidence of migraine headaches in a community sample: results from the Baltimore Epidemiologic Catchment area follow-up study. Arch Gen Psychiatry. 2000;57:945-950.
76. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care. 2004;10:313-320.